Investigators from Beatson Institute for Cancer Research have published findings from a study that applied untargeted metabolic profiling to identify novel therapeutic targets for colorectal cancer (CRC). Genetically engineered mouse models and multimodal mass spectrometry-based metabolomics were used to analyze metabolic effects of common genetic mutations in CRC.